COMMUNIQUÉS West-GlobeNewswire

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
23/02/2026
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast cancer Artios is launching a global randomized Phase 2 study to evaluate [...]
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced participation in one-on-one [...]
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
23/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Seismic Therapeutic to Participate in Upcoming Investor Conferences
23/02/2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc. , the machine learning immunology company, today announced that company management will participate in the following investor conferences: TD [...]
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
23/02/2026
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December [...]
LENZ Therapeutics to Present at Upcoming Investor Conferences
23/02/2026
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine ophthalmologic solution) 1. [...]
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
23/02/2026
DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to [...]
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
23/02/2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
23/02/2026
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care [...]
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
23/02/2026
MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
TOMI Environmental Solutions Receives Biocidal Product Approvals in Great Britain and Northern Ireland
23/02/2026
Health and Safety Executive (HSE) grants Authorization Nos.: GB-2016-1042 and NI-2026-1350 FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader [...]
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
23/02/2026
CagriSema achieved 23% weight loss after 84 weeks of treatment CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks 1 Additional [...]
RE+Vitalize Health and Nutrition Announces Initiative to Advance Clean and Transparent Supplement Standards
23/02/2026
Elizabeth City, NC, Feb. 23, 2026 (GLOBE NEWSWIRE) -- RE+Vitalize Health and Nutrition, a retail health and nutrition brand based in Elizabeth City, announced an initiative focused on advancing clean and transparent [...]
Pulselight platform now available to NHS via £10bn Fortrus Framework
23/02/2026
Pulselight’s platform can now be procured for NHS organisations via this pre-approved route to market LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pulselight, a leading healthcare data analytics provider, is now an [...]
Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101
23/02/2026
MUTTENZ, Switzerland, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Opterion Health AG today announced that the first patient has been successfully enrolled in its Phase 1 SPARC trial. This marks the official start of the company’s [...]
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
23/02/2026
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be [...]
argenx to Present at TD Cowen 46th Annual Healthcare Conference
23/02/2026
February 23, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
22/02/2026
- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1 - - Five total [...]
Gyder Surgical announces first commercial surgical cases in the United States performed by Dr. Paul M. Lombardi, M.D., at the Tri-County Orthopedics’ Joint Replacement Institute outpatient center
22/02/2026
The GYDER® Navigation System is the world’s first commercially available pin-less & image-less computer assisted technology for real time guidance during Total Hip Arthroplasty using the Anterior Approach PALO ALTO [...]

Pages